AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie neuroscience Portfolio — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
10,767
Period ended Dec 31, 2025
Change on a year earlier
+19.6%
8,999 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuroscience Portfolio — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10,767 | +19.6% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 8,999 | +16.6% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 7,717 | +18.2% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 6,528 | +10.1% | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 5,927 | +69.5% | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 3,496 | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
Breakdown
What makes up neuroscience portfolio — worldwide net revenues ($m)
- Neuroscience Portfolio — U.S. net revenues ($M)9,340 · FY2025
- Neuroscience Portfolio — International net revenues ($M)1,427 · FY2025
- Neuroscience Portfolio — Worldwide reported growth YoY (%)19.6% · FY2025
- Neuroscience Portfolio — Worldwide operational (constant-currency) growth YoY (%)19.4% · FY2025
- Vraylar (cariprazine) — Worldwide net revenues ($M)3,621 · FY2025
- Botox Therapeutic (onabotulinumtoxinA) — Worldwide net revenues ($M)3,769 · FY2025
- Ubrelvy (ubrogepant) — Worldwide net revenues ($M)1,271 · FY2025
- Qulipta (atogepant) — Worldwide net revenues ($M)1,036 · FY2025
- Vyalev (foscarbidopa/foslevodopa) — Worldwide net revenues ($M)482 · FY2025
- Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — Worldwide net revenues ($M)381 · FY2025
- Other Neuroscience — Worldwide net revenues ($M)207 · FY2025
Cite this data
StockData. (2026). AbbVie Neuroscience Portfolio — Worldwide net revenues ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_neuro_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.